scholarly journals Anxiety, depression, and cardiac outcomes after a first diagnosis of acute coronary syndrome.

2018 ◽  
Vol 37 (12) ◽  
pp. 1115-1122 ◽  
Author(s):  
Paolo Ossola ◽  
Maria Lidia Gerra ◽  
Chiara De Panfilis ◽  
Matteo Tonna ◽  
Carlo Marchesi
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Cardiac Outcomes ◽  
Anxiety Depression ◽  
First Diagnosis

scholarly journals Positive effect of polyprenol-containing drug on anxiety, depression and cognitive disorders in patients with acute coronary syndrome

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
EI Tsoi ◽  
EV Vyshlov ◽  
VV Ryabov
Keyword(s):  
Acute Coronary Syndrome ◽  
Cognitive Functions ◽  
Controlled Trial ◽  
Cognitive Disorders ◽  
Original Method ◽  
Study Group ◽  
Double Blind ◽  
Coronary Syndrome ◽  
Anxiety Depression ◽  
Positive Effect

Abstract Funding Acknowledgements Type of funding sources: None. Introduction. Polyprenols (natural isoprenoid lipids) are precursors of dolichols which is present in every cell and involved in a dolicholphosphate pathway. It seems the polyprenols from plants can be used for a substitution therapy in dolicholphosphate pathway disorders. There is one polyprenol-containing drug in Russia – Ropren® which contains polyprenols isolated by the original method from needles of European spruce. In clinical trials hepatoprotective, hypolipidemic effects of Ropren® in patients with liver pathology and positive effect in alcoholic psychosis and Alzheimer"s disease were founded. Considering that the myocardial infarction is often accompanied by the phenomena of anxiety, depression and decreased cognitive functions that impair prognosis of the disease the search for a drug aimed at reducing the expression of these conditions is relevant. Purpose. To study the effects of Ropren® on anxiety-depressive condition and cognitive functions in patients with acute coronary syndrome. Methods. Our registered single-center, randomized, double-blind, placebo-controlled trial "POLYNCOR" were included patients (n = 68) with acute coronary syndrome hospitalized on the first day from the beginning of the symptoms. All patients received standard therapy (including atorvastatin 40 mg) and were randomized on 2 groups: the 1st group (n = 34) received Ropren® 8 drops during а meal 3 times a day (144 mg/day) for 3 weeks then 3 drops 3 times a day (90 mg/day) for 5 weeks; the 2nd group 2 (n = 34) received placebo with the same dosage regimen. On the 3rd, 10th days of hospitalization and after 2 months of therapy the following parameters were analyzed: the level of depression on the CES-D scale, anxiety on the Taylor and Sheehan scales, cognitive functions were assessed on the Montreal Cognitive Assessment Scale (MoCA). Statistical data processing was performed using the Statistica v.10.0 package using nonparametric analysis methods. The results are presented as Me (Q1; Q3). Results. At discharge there were no differences between groups and the majority of the patients had signs of anxiety, depression and decreased cognitive functions. After 2 months of therapy comparing with the 3rd day of hospitalization the decrease of anxiety score: 2.5 (1.5; 7.5) vs. 15.5 (9,5; 20,5) respectively (p< 0.05) according to Taylor scale and 5.5 (5; 14) vs. 30 (17,5; 39) respectively (p< 0.05) according to Sheehan scale, and depression score: 8 (6.5; 9.5) vs. 18 (15,5; 20,5) respectively (p< 0.05) according to CES-D scale were founded in the study group. Also in the study group cognitive functions score were improved from 23 (21; 25) to 26.5 (25; 28) (p< 0.05) according to MoCA scale. Conclusion. Polyprenol-containing drug Ropren® contributes to significant reduction of anxiety, depression and improving of cognitive functions in patients with acute coronary syndrome after 2 months of therapy.

Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome

JAMA ◽  
2018 ◽  
Vol 320 (20) ◽  
pp. 2151
Author(s):  
Brett D. Thombs ◽  
Roy C. Ziegelstein
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

scholarly journals Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study

2020 ◽  
pp. 1-11
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Hee-Ju Kang ◽  
Seon-Young Kim ◽  
Ju-Wan Kim ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Depressive Disorder ◽  
Randomised Clinical Trial ◽  
Diagnosis And Treatment ◽  
Depression Screening ◽  
Cardiac Events ◽  
Coronary Syndrome ◽  
Cardiac Outcomes ◽  
Appropriate Treatment

Abstract Background To investigate the impacts of depression screening, diagnosis and treatment on major adverse cardiac events (MACEs) in acute coronary syndrome (ACS). Methods Prospective cohort study including a nested 24-week randomised clinical trial for treating depression was performed with 5–12 years after the index ACS. A total of 1152 patients recently hospitalised with ACS were recruited from 2006 to 2012, and were divided by depression screening and diagnosis at baseline and 24-week treatment allocation into five groups: 651 screening negative (N), 55 screening positive but no depressive disorder (S), 149 depressive disorder randomised to escitalopram (E), 151 depressive disorder randomised to placebo (P) and 146 depressive disorder receiving medical treatment only (M). Results Cumulative MACE incidences over a median 8.4-year follow-up period were 29.6% in N, 43.6% in S, 40.9% in E, 53.6% in P and 59.6% in M. Compared to N, screening positive was associated with higher incidence of MACE [adjusted hazards ratio 2.15 (95% confidence interval 1.63–2.83)]. No differences were found between screening positive with and without a formal depressive disorder diagnosis. Of those screening positive, E was associated with a lower incidence of MACE than P and M. M had the worst outcomes even compared to P, despite significantly milder depressive symptoms at baseline. Conclusions Routine depression screening in patients with recent ACS and subsequent appropriate treatment of depression could improve long-term cardiac outcomes.

Impact of Suicidal Ideation on Long-Term Cardiac Outcomes in Patients with Acute Coronary Syndrome: Sex-Specific Differences

2018 ◽  
Vol 87 (5) ◽  
pp. 311-312 ◽  
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Hee-Joon Lee ◽  
Hee-Ju Kang ◽  
Kyung-Yeol Bae ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Suicidal Ideation ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome—Reply

JAMA ◽  
2018 ◽  
Vol 320 (20) ◽  
pp. 2152
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Jin-Sang Yoon
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

scholarly journals Can troponin I measurement predict short-term serious cardiac outcomes in patients presenting to the emergency department with possible acute coronary syndrome?

CJEM ◽  
2004 ◽  
Vol 6 (01) ◽  
pp. 22-30 ◽  
Author(s):  
Stephen A. Hill ◽  
P.J. Devereaux ◽  
Lauren Griffith ◽  
John Opie ◽  
Matthew J. McQueen ◽  
...  
Keyword(s):  
Emergency Department ◽  
Acute Coronary Syndrome ◽  
Troponin I ◽  
Tertiary Care ◽  
Cardiovascular Death ◽  
Care Hospital ◽  
Likelihood Ratios ◽  
Coronary Syndrome ◽  
Cardiac Outcomes ◽  
Cardiac Outcome

ABSTRACT Objective: To determine the ability of troponin I (TnI) measurement to predict the likelihood of a serious cardiac outcome over the subsequent 72 hours in patients presenting to the emergency department (ED) with symptoms suggestive of an acute coronary syndrome. Methods: This prospective observational study enrolled consecutive patients presenting to 2 urban tertiary care hospital EDs over a 5-week period. Eligible patients included those for whom a TnI test was ordered within 24 hours of arrival and in whom no serious cardiac outcome occurred before the test result was available. Patients were followed for 72 hours and serious cardiac outcomes documented; these included cardiovascular death, myocardial infarction, congestive heart failure, serious arrhythmia and refractory pain. We calculated likelihood ratios (LRs) to describe the association of the TnI result with serious cardiac outcomes. Results: Of the 352 enrolled patients, 20 had a serious cardiac outcome within 72 hours of ED presentation. The derived LRs (and 95% confidence interval [CI]) were 0.5 (0.3–0.9) for TnI values <0.5 µg/L, 1.6 (0.4–6.5) for TnI values from 0.5 to 2.0 µg/L, 5.8 (1.7–19.5) for TnI values from >2.0 to 10.0 µg/L and 14.4 (4.8–42.9) for TnI values >10.0 µg/L. Conclusions: TnI values >2.0 µg/L are associated with an increased probability of serious cardiac outcomes within 72 hours. TnI values between 0.5 and 2.0 µg/L are weakly positive predictors. TnI values <0.5 µg/L have LRs in the range of 0.5 and thus are weakly negative predictors, not substantially decreasing the likelihood of serious cardiac outcomes, particularly in patients with a moderate or high pretest probability.

Sign in / Sign up

Export Citation Format

Share Document